Posaconazole oral/injection and Rifampin Oral, Intravenous
Determining the interaction of Posaconazole oral/injection and Rifampin Oral, Intravenous and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Ask your doctor before using rifAMPin together with posaconazole. Using these medications together may decrease the effects of posaconazole. Contact your doctor if your condition or infection worsens. If your doctor prescribes these medications together, you may need a dose adjustment or special tests to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:GENERALLY AVOID: Coadministration with a rifamycin may result in decreased plasma concentrations of posaconazole. The mechanism is induction of posaconazole clearance via the UDP-glucuronosyltransferase glucuronidation and P-glycoprotein efflux pathways. According to product labeling, administration of posaconazole (200 mg tablets once a day for 10 days) with rifabutin (300 mg once a day for 17 days) resulted in reduced posaconazole mean peak plasma concentration (Cmax) by 57% and systemic exposure (AUC) by 51%. Treatment failure could result. Conversely, posaconazole is an inhibitor of CYP450 3A4 and can increase the plasma levels of rifabutin, which is thought to be partially metabolized by the isoenzyme. Rifabutin Cmax rose by 31% and AUC by 72% during coadministration of posaconazole.
MANAGEMENT: Use of posaconazole in combination with a rifamycin should generally be avoided unless the potential benefit outweighs the risk. If coadministration is necessary, patient response to the antifungal agent must be closely monitored. When administered with rifabutin, close clinical and laboratory monitoring for rifabutin toxicity including leukopenia, uveitis, arthralgias, and skin discoloration are also recommended.
- "Product Information. Noxafil (posaconazole)." Schering-Plough Corporation, Kenilworth, NJ.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Generic Name: posaconazole
Brand name: Noxafil
Synonyms: Posaconazole (oral/injection), Posaconazole
Generic Name: rifampin
Brand name: Rifadin, Rifadin IV, Rimactane
Synonyms: Rifampin
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Posaconazole oral/injection-Rifampin, Isoniazid, and Pyrazinamide
- Posaconazole oral/injection-Rifamycin
- Posaconazole oral/injection-Rifamycin Sodium
- Posaconazole oral/injection-Rifapentine
- Posaconazole oral/injection-Rifater
- Posaconazole oral/injection-Rifaximin
- Rifampin Oral, Intravenous-Posaconazole Tablets
- Rifampin Oral, Intravenous-PosiFlush flush
- Rifampin Oral, Intravenous-Positive Skin Test Control - Histamine
- Rifampin Oral, Intravenous-Posture
- Rifampin Oral, Intravenous-Potaba
- Rifampin Oral, Intravenous-Potaba (Potassium P-Aminobenzoate Capsules)